Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication

Journal of Medicinal Chemistry

Volumn 56, Issue 22, 2013, Pages 9222-9241

  Sindac, Janice A ^b   Barraza, Scott J ^b   Dobry, Craig J ^c   Xiang, Jianming ^d   Blakely, Pennelope K ^d   Irani, David N ^d   Keep, Richard F ^d   Miller, David J ^c   Larsen, Scott D ^a,b  

^a Vahlteich Medicinal Chemistry Core   (United States)

^b Center for Pharmacoepidemiology and Pharmacoeconomic Research   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N (3 METHOXYPHENETHYL)PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N (4 CHLOROPHENETHYL)PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N (4 FLUOROPHENETHYL)PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N (4 ISOPROPYLPHENETHYL)PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N (4 METHOXYPHENETHYL)PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N [(1 METHYL 1H IMIDAZOL 4 YL)METHYL]PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N [(1 METHYL 1H PYRAZOL 3 YL)METHYL]PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N [(1 METHYLPIPERIDIN 4 YL)METHYL]PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N [(2,3 DIHYDROFURO[2,3 C]PYRIDIN 3 YL) METHYL]PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N [1 (PYRIDIN 4 YL)ETHYL]PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N [2 (PYRIDIN 2 YL)ETHYL]PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N [2 (PYRIDIN 3 YL)ETHYL]PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N [2 (PYRIDIN 4 YL)ETHYL]PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N [2 (PYRIDIN 4 YL)PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N [2 METHYL 2 (PYRIDIN 4 YL)PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N [3 (PYRIDIN 4 YL)PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N METHYL N [2 (PYRIDIN 4 YL)ETHYL]PIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL] N,N DIMETHYLPIPERIDINE 4 CARBOXAMIDE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 YL] [4 [2 (HYDROXYMETHYL)PYRROLIDINE 1 CARBONYL]PIPERIDIN 1 YL] METHANONE; 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 YL] N [4 (4 METHYLPIPERAZINE 1 CARBONYL)PIPERIDIN 1 YL]METHANONE; [1 (4 CHLOROBENZYL) 1H INDOL 2 YL][4 (MORPHOLINE 4 CARBONYL)PIPERIDIN 1 YL]METHANONE; [1 (4 CHLOROBENZYL) 1H INDOL 2 YL][4 (PYRROLIDINE 1 CARBONYL)PIPERIDIN 1 YL]METHANONE; AMIDE; INDOLE 2 CARBOXAMIDE INHIBITOR; INDOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 1; N [2 (1H IMIDAZOL 1 YL)ETHYL] 1 [1 (4 CHLOROBENZYL) 1H INDOLE 2 CARBONYL]PIPERIDINE 4 CARBOXAMIDE; N BENZYL 1 [1 (4 CHLOROBENZYL) 1 INDOLE 2 CARBONYL] N METHYL PIPERIDINE 4 CARBOXAMIDE; RHODAMINE 123; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALPHA VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENCY; HUMAN; HUMAN CELL; LIVER MICROSOME; MDCK CELL; MOUSE; NEUROTROPIC ALPHAVIRUS; NONHUMAN; SINDBIS VIRUS; STRUCTURE ACTIVITY RELATION; VIRUS INFECTION; VIRUS REPLICATION; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ANIMALS; ANTIVIRAL AGENTS; BLOOD-BRAIN BARRIER; CELL LINE; DRUG DESIGN; ENCEPHALITIS VIRUS, WESTERN EQUINE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INDOLES; MICE; MOLECULAR WEIGHT; P-GLYCOPROTEIN; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84889253069     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401330r     Document Type: Article

References (25)

1. Griffin, D. E., Alphaviruses. In Fields Virology, 4th ed.; D.M. Knipe, P. M. H., Griffin, D.E., Lamb, R.A, Martin, M.A., Roizman, B., Straus, S.S, Ed.; Lippincott Williams & Wilkins: Philadelphia, 2001; pp 917-962.
2. Gubler, D. J. The global emergence/resurgence of arboviral diseases as public health problems Arch. Med. Res. 2002, 33, 330-342 (Pubitemid 35299553)
3. Bronze, M. S.; Huycke, M. M.; Machado, L. J.; Voskuhl, G. W.; Greenfield, R. A. Viral agents as biological weapons and agents of bioterrorism Am. J. Med. Sci. 2002, 323, 316-325 (Pubitemid 34651569)
4. Sidwell, R. W.; Smee, D. F. Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control Antiviral Res. 2003, 57, 101-111 (Pubitemid 36254724)
5. NIH/NIAID Category A, B, & C Priority Pathogens; National Institute of Allergy and Infectious Diseases: Bethesda, MD, 2013, http://www.niaid.nih. gov/topics/BiodefenseRelated/Biodefense/research/Pages/CatA.aspx.
6. Peng, W.; Peltier, D. C.; Larsen, M. J.; Kirchhoff, P. D.; Larsen, S. D.; Neubig, R. R.; Miller, D. J. Identification of thieno[3,2- b ]pyrrole derivatives as novel small molecule inhibitors of neurotropic alphaviruses J. Infect. Dis. 2009, 199, 950-957
7. Sindac, J. A.; Yestrepsky, B. D.; Barraza, S. J.; Bolduc, K. L.; Blakely, P. K.; Keep, R. F.; Irani, D. N.; Miller, D. J.; Larsen, S. D. Novel Inhibitors of Neurotropic Alphavirus Replication That Improve Host Survival in a Mouse Model of Acute Viral Encephalitis J. Med. Chem. 2012, 55, 3535-3545
8. Begley, D. J. ABC transporters and the blood-brain barrier Curr. Pharm. Des. 2004, 10, 1295-1312 (Pubitemid 38559749)
9. Frost, J. M.; Dart, M. J.; Tietje, K. R.; Garrison, T. R.; Grayson, G. K.; Daza, A. V.; El-Kouhen, O. F.; Yao, B. B.; Hsieh, G. C.; Pai, M.; Zhu, C. Z.; Chandran, P.; Meyer, M. D. Indol-3-ylcycloalkyl Ketones: Effects of N1 Substituted Indole Side Chain Variations on CB2 Cannabinoid Receptor Activity J. Med. Chem. 2010, 53, 295-315
10. Beyer, T. A.; Chambers, R. J.; Li, M.; Morrell, A. I.; Thompson, D. D. Pyrido[2,3- d ]pyrimidine-2,4-diamines as PDE 2 inhibitors. WO 2005/061497 A1, 2005.
11. Kamal, A.; Rajender; Reddy, D. R.; Reddy, M. K.; Balakishan, G.; Shaik, T. B.; Chourasia, M.; Sastry, G. N. Remarkable enhancement in the DNA-binding ability of C2-fluoro substituted pyrrolo[2,1- c ][1,4]benzodiazepines and their anticancer potential Bioorg. Med. Chem. 2009, 17, 1557-1572
12. Leroy, J.; Porhiel, E.; Bondon, A. Synthesis and characterization of partially β-fluorinated 5,10,15,20-tetraphenylporphyrins and some derivatives Tetrahedron 2002, 58, 6713-6722
13. Katritzky, A. R.; Scriven, E. F. V.; Majumder, S.; Akhmedova, R. G.; Vakulenko, A. V.; Akhmedov, N. G.; Murugan, R.; Abboud, K. A. Preparation of nitropyridines by nitration of pyridines with nitric acid Org. Biomol. Chem. 2005, 3, 538-541 (Pubitemid 40285722)
14. Guandalini, L.; Martini, E.; Gualtieri, F.; Romanelli, M. N.; Varani, K. Design, synthesis and preliminary pharmacological evaluation of rigid analogues of the nicotinic agonist 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP) ARKIVOC 2004, 286-300 (Pubitemid 38773756)
15. Kerns, E. H.; Di, L. Solubility. In Drug-like Properties: Concepts, Structure Design and Methods; Academic Press: San Diego, 2008; Chapter 7, pp 56-85.
16. Bevan, C. D.; Lloyd, R. S. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates Anal. Chem. 2000, 72, 1781-1787 (Pubitemid 30220169)
17. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 2003, 38, 223-232 (Pubitemid 36349665)
18. Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. PAMPA-critical factors for better predictions of absorption J. Pharm. Sci. 2007, 96, 2893-2909 (Pubitemid 350221191)
19. Ruell, J. A.; Tsinman, O.; Avdeef, A. Acid-base cosolvent method for determining aqueous permeability of amiodarone, itraconazole, tamoxifen, terfenadine and other very insoluble molecules Chem. Pharm. Bull. 2004, 52, 561-565 (Pubitemid 41701905)
20. Forster, S.; Thumser, A. E.; Hood, S. R.; Plant, N. Characterization of Rhodamine-123 as a Tracer Dye for Use in in Vitro Drug Transport Assays PLoS One 2012, 3, e33252
21. Larsen, S. D.; Wilson, M. W.; Abe, A.; Shu, L.; George, C. H.; Kirchhoff, P.; Showalter, H. D.; Xiang, J.; Keep, R. F.; Shayman, J. A. Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain J. Lipid Res. 2011, 53, 282-291
22. Hitchcock, S. A. Structural modifications that alter the P-glycoprotein efflux properties of compounds J. Med. Chem. 2012, 55, 4877-4895
23. Bianchi, T. I.; Aviles, G.; Sabattini, M. S. Biological characteristics of an enzootic subtype of western equine encephalomyelitis virus from Argentina Acta Virol. 1997, 41, 13-20 (Pubitemid 27462795)
24. Larsen, S. D.; Sindac, J. A.; Barazza, S.; Miller, D. J. Preparation of pyrrolyl(or imidazolyl) piperidinyl methanone derivatives as arbovirus inhibitors. US 20120252807 A1, 20121004, 2012.
25. Lee, J.; Kang, S. U.; Lim, J. O.; Choi, H. K.; Jin, M. K.; Toth, A.; Pearce, L. V.; Tran, R.; Wang, Y.; Szabo, T.; Blumberg, P. M. N -[4-(Methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: analysis of structure-activity relationships for the "C-Region" Bioorg. Med. Chem. 2004, 12, 371-385 (Pubitemid 38064209)